Physician profile
Farid Roman
NPI 1851366355
$61,658.17
in general payments reported to CMS, 2019-2025
75 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $14K · 2021: $7,101 · 2022: $2,716 · 2023: $2,482 · 2024: $2,508 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,556 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,556.10 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21,654.98 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $18,870.28 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,260.74 | 2019-2025 | Jardiance, Glyxambi, Synjardy |
| Lilly USA, LLC | $4,368.89 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $2,925.95 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Infinity |
| Medtronic Minimed, INC. | $1,405.18 | 2019-2020 | |
| Dexcom, INC. | $819.91 | 2019-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $634.04 | 2019-2025 | Omnipod |
| Senseonics, Incorporated | $450.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $425.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $288.15 | 2019-2021 | |
| Medtronic, INC. | $238.15 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Abbvie INC. | $236.67 | 2019-2024 | Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $211.62 | 2019-2022 | |
| Amarin Pharma, INC. | $205.19 | 2019-2022 |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.